🇺🇸 FDA
Patent

US 10261095

Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment

granted A61KA61K2039/505A61P

Quick answer

US patent 10261095 (Predictive biomarkers of clinical response to anti-LPS immunoglobulin treatment) held by Julius-Maximilians-Universitat Wurzburg expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Julius-Maximilians-Universitat Wurzburg
Grant date
Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61P, A61P1/00, A61P1/02